Skip to content

Arcus Biosciences

US · RCUS #2467 by market cap Listed 2018
15.62 -0.16 -1.01%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:39

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership fell 10.3 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
87.81% -10.30pp
Institutions
297 +8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund43.40%
Public Company24.36%
Hedge Fund15.73%
Individual/Insider3.19%
VC/PE Fund2.48%
Private Company0.78%
Government Pension Fund0.64%
Insurance Company0.25%
Endowment Fund0.13%
Other9.04%

Top holders as of 2026-09-30

Gilead Sciences, Inc. 21.82% · 31.42M sh
BlackRock 11.68% · 16.82M sh
Wellington Management Group 4.09% · 5.90M sh
State Street Global Advisors 3.87% · 5.57M sh
Montanova Capital, LLC 3.32% · 4.78M sh
Vanguard Portfolio Management, LLC 3.08% · 4.44M sh
FMR 3.08% · 4.43M sh
Vanguard Capital Management, LLC 2.73% · 3.93M sh
Citadel Advisors LLC 2.18% · 3.14M sh
Woodline Partners LP 2.09% · 3.01M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 28 sells

NameRoleStake
Gilead Sciences, Inc. -- 21.82%
Terry Rosen Chairperson & CEO 1.80%
Juan Jaen Co- Founder & President 0.76%
Yasunori Kaneko Lead Independent Director 0.14%
Kathryn Falberg Independent Director 0.12%
Jennifer Jarrett Former Chief Operating Officer 0.09%
Carolyn Tang General Counsel 0.08%
David Lacey Independent Director & Member of Scientific Advisory Board 0.05%
Antoni Ribas Independent Director & Member of Scientific Advisory Board 0.03%
Andrew Perlman Independent Director 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-20 Alexander Azoy Chief Accounting Officer Derivative Exercise and Sale -2,827 $15.44–30.00
2026-07-09 Juan Jaen Co- Founder & President Open Market Disposition -68,569 $28.61–30.05
2026-06-23 Juan Jaen Co- Founder & President Automatic Disposition -31,431 $27.03–29.66
2026-06-10 Yasunori Kaneko Lead Independent Director Other Acquisition +5,700 --
2026-06-10 Kathryn Falberg Independent Director Other Acquisition +5,700 --
2026-06-10 Andrew Perlman Independent Director Other Acquisition +5,700 --
2026-06-10 C. Machado Independent Director Other Acquisition +5,700 --
2026-06-10 David Lacey Independent Director & Member of Scientific Advisory Board Other Acquisition +5,700 --
2026-06-10 Antoni Ribas Independent Director & Member of Scientific Advisory Board Other Acquisition +5,700 --
2026-06-10 Carolyn Tang General Counsel Derivative Exercise and Retained +34,090 $2.57
2026-06-10 Nicole Lambert Independent Director Other Acquisition +5,700 --
2026-05-31 Alexander Azoy Chief Accounting Officer Automatic Disposition -2,562 $25.77
2026-05-10 Robert Goeltz Principal Financial Officer & CFO Open Market Disposition -7,763 $25.63
2026-05-05 Jennifer Jarrett Former Chief Operating Officer Intent to Sell (Form 144) -77,793 $24.60
2026-04-22 Jennifer Jarrett Former Chief Operating Officer Intent to Sell (Form 144) -53,826 $25.20
2026-04-07 Jennifer Jarrett Former Chief Operating Officer Intent to Sell (Form 144) -70,000 $22.57
2026-01-22 Juan Jaen Co- Founder & President Other Acquisition +31,000 --
2026-01-22 Juan Jaen Co- Founder & President Other Derivative Acquisition +126,000 $22.13
2026-01-22 Robert Goeltz Principal Financial Officer & CFO Other Acquisition +24,000 --
2026-01-22 Robert Goeltz Principal Financial Officer & CFO Other Derivative Acquisition +96,000 $22.13

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.

Arcus Biosciences discussion 0 comments

Add a comment